Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05326464 · ClinicalTrials.gov registry record · Phase 3
Tofacitinib in Recurrent GBM Patients
A Phase 3 study of Glioblastoma, sponsored by University of Texas Southwestern Medical Center.
- Active
- Registry status
- Phase 3
- Development phase
- 17
- Enrollment target
- 1
- Study location
NCT05326464: Active Phase 3 study of Glioblastoma, sponsored by University of Texas Southwestern Medical Center.
NCT05326464 is a Phase 3 study of Glioblastoma that is active but no longer recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 17 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05326464, a Phase 3 study of Glioblastoma, is active but no longer recruiting, sponsored by University of Texas Southwestern Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 17 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine the effects of Tofacitinib in patients with recurrent Glioblastoma.
Primary Outcome
Median progression-free survival from initiation of Tofacitinib until disease progression as defined by the RANO criteria, unacceptable toxicity, withdrawal of consent, or discontinuation from the trial for any other reason.
Conditions Studied
Interventions
- DRUG Tofacitinib 10mg
Study Locations (1)
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2022-10-07 |
| Est. Completion | 2027-06-01 |
| Phase | Phase 3 |
What the registry record for NCT05326464 still lists
NCT05326464 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Tofacitinib 10mg is the first listed.
NCT05326464 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05326464 about?
NCT05326464 is a clinical study titled "Tofacitinib in Recurrent GBM Patients". The purpose of this study is to examine the effects of Tofacitinib in patients with recurrent Glioblastoma.
What is the current status of trial NCT05326464?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 17 participants. The study started on 2022-10-07. Estimated completion is 2027-06-01.
What conditions does trial NCT05326464 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT05326464?
The interventions under investigation include: Tofacitinib 10mg (DRUG).
Who is sponsoring clinical trial NCT05326464?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05326464 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05326464's enrollment target sits among peer trials
17 166th of 199 higher than 31 of 199 other Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
RECRUITING · Phase 3
-
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
RECRUITING · Phase 3
-
Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients
RECRUITING · Phase 3
-
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
RECRUITING · Phase 3
-
Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
RECRUITING · Phase 3
-
Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI